Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
3 Growth Stocks That Could Disrupt the Healthcare Industry
03:29pm, Monday, 13'th Mar 2023
Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.
Neurocrine Biosciences to Participate at Investor Conferences in March
04:01pm, Wednesday, 08'th Mar 2023
Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX
NBIX Stock: 4.55% Decrease Explanation
02:33am, Tuesday, 07'th Feb 2023
The stock price of Neurocrine Biosciences (NASDAQ: NBIX) fell by 4.55% in the most recent trading session. This is why.
Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Call Transcript
02:52pm, Monday, 06'th Feb 2023
Start Time: 08:00 January 1, 0000 9:02 AM ET Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Ab
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
09:47am, Monday, 06'th Feb 2023
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
08:56am, Monday, 06'th Feb 2023
Neurocrine Biosciences reported strong fourth-quarter profit growth on Monday and beat fourth-quarter estimates. But NBIX stock was flat.
Neurocrine Biosciences: Stencil In These Important Dates
12:55pm, Wednesday, 25'th Jan 2023
Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February
Neurocrine Biosciences: Scope For Valuation Upside With Ingrezza Numbers
04:04am, Tuesday, 24'th Jan 2023
After a strong performance in H2 FY22, Neurocrine Biosciences saw a sharp reversal into the new year. The question is, does this present an opportunity to buy or not?
Stocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A Wildcards
03:00pm, Saturday, 21'st Jan 2023 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
Why Voyager Therapeutics Stock Is Sinking This Week
05:08pm, Friday, 20'th Jan 2023 The Motley Fool
Investors are taking profits on this red-hot stock this week.
Voyager Therapeutics Inc (NASDAQ:VYGR) shares have jumped on the news that the biotechnology company has entered into a strategic collaboration with Neurocrine Biosciences (NASDAQ:NBIX) Inc to advance
6 Favorite Biotech Bets For 2023
10:48am, Monday, 09'th Jan 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's
Voyager, Neurocrine ink gene-therapy deal
08:15am, Monday, 09'th Jan 2023
Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, +0.06% to develop and commerciali
Have A Look At William Blair's Top Biotech Picks For 2023
06:32pm, Sunday, 25'th Dec 2022 Benzinga
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Seagen Inc.'s (NASD
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
01:00pm, Wednesday, 07'th Dec 2022 Benzinga
Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with
